(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of 29.43% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Voyager Therapeutics's revenue in 2026 is $36,494,000.On average, 13 Wall Street analysts forecast VYGR's revenue for 2026 to be $2,539,385,850, with the lowest VYGR revenue forecast at $532,915,751, and the highest VYGR revenue forecast at $7,975,005,671. On average, 13 Wall Street analysts forecast VYGR's revenue for 2027 to be $3,755,605,936, with the lowest VYGR revenue forecast at $898,283,274, and the highest VYGR revenue forecast at $7,799,179,726.
In 2028, VYGR is forecast to generate $4,731,772,249 in revenue, with the lowest revenue forecast at $1,167,762,214 and the highest revenue forecast at $14,085,410,425.